⌘K
OverviewStock screenerAnalyst actionsCalendar
MarketsInvestorsSign in
StockUnited StatesNYSE

BHVN

Biohaven Ltd.

Healthcare · Biotechnology

15.00USD

+0.2800 (+1.90%)

DescriptionHistoricalFinancialsRelative ValueResearchNewsDiscussionOptionsPrice Chart ↗Fundamental Chart ↗

Estimates and surprises

Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.

PeriodConsensus EPS90 days agoRevisions up (30d)Revisions down (30d)
Current quarter$-0.21▲$-0.5703
Next quarter$-0.46▲$-0.4912
Current year$-1.97▲$-2.403
Next year$-1.94▲$-1.9522

Recent quarters

Beat in 3 of the last 4

QuarterEstimateActualSurprise
2026-06-30$-0.61$-0.78-0.17 (-27.6%)
2026-03-31$-0.76$-0.69+0.07 (+9.7%)
2025-12-31$-0.96$-0.9+0.06 (+5.8%)
2025-09-30$-1.54$-1.47+0.07 (+4.8%)

Wall Street coverage

82 ratings from 18 firms

Ratings are attributed to the research firm, not to individual analysts. See every ticker.

FirmActionRatingPrice TargetDate
RBC CapitalDowngraded from OutperformSector Perform$23 $19Sep 8, 2026
Morgan StanleyMaintainedOverweight$18 $19Aug 12, 2026
RBC CapitalMaintainedOutperform$22 $23Aug 11, 2026
B of A SecuritiesDowngraded from NeutralUnderperform$12 $11Jun 29, 2026
HC Wainwright & Co.ReiteratedNeutral$10May 26, 2026
Morgan StanleyMaintainedOverweight$21 $18May 13, 2026
RBC CapitalMaintainedOutperform$23 $22May 5, 2026
CitigroupMaintainedBuy$14 $17Apr 2, 2026
TD CowenMaintainedBuy$15 $30Mar 11, 2026
HC Wainwright & Co.MaintainedNeutral$11 $10Mar 4, 2026
RBC CapitalMaintainedOutperform$22 $23Mar 3, 2026
RBC CapitalUpgraded from Sector PerformOutperform$9 $22Jan 21, 2026
Morgan StanleyMaintainedOverweight$26 $21Jan 6, 2026
HC Wainwright & Co.ReiteratedNeutral$11Dec 26, 2025
HC Wainwright & Co.Downgraded from BuyNeutral$30 $11Dec 3, 2025
UBSDowngraded from BuyNeutral$26 $11Nov 26, 2025
JP MorganMaintainedOverweight$47 $15Nov 20, 2025
Morgan StanleyMaintainedOverweight$54 $26Nov 18, 2025
BTIGReiteratedBuy$16Nov 18, 2025
CitigroupMaintainedBuy$28 $14Nov 13, 2025
BernsteinDowngraded from OutperformMarket Perform$34 $9Nov 6, 2025
RBC CapitalMaintainedSector Perform$19 $9Nov 6, 2025
BTIGMaintainedBuy$33 $16Nov 6, 2025
William BlairDowngraded from OutperformMarket Perform—Nov 5, 2025
TD CowenMaintainedBuy$50 $15Nov 5, 2025

Insider transactions

21 filings from 8 insiders · 0 buy / 0 sell over 6m

Officers and directors of BHVN, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.

InsiderActionSharesPriceValueDate
MEHTA KISHANDirectorGift17.3k——Mar 17, 2026
BUTEN MATTHEWChief Financial OfficerOther4.3k——Jan 5, 2026
CLARK GEORGE C.OfficerOther2.5k——Jan 5, 2026
CAR BRUCEOfficerOther4.8k——Jan 5, 2026
CORIC VLADIMIRChief Executive OfficerOther14.3k——Jan 5, 2026
GENTILE KIMBERLY AOfficerOther3.8k——Jan 5, 2026
CLARK GEORGE C.OfficerBuyindirect17.0k$8.52$145kNov 17, 2025
CORIC VLADIMIRChief Executive OfficerBuyindirect666.7k$7.50$5.00MNov 13, 2025
BAILEY GREGORY HUGHDirectorBuy400.0k$7.50$3.00MNov 13, 2025
CHILDS JOHN WDirectorBuyindirect3.33M$7.50$25.00MNov 13, 2025
CHILDS JOHN WDirectorBuyindirect29.3k$30.43$892kMar 4, 2025
CHILDS JOHN WDirectorBuyindirect32.7k$30.39$996kMar 4, 2025
BUTEN MATTHEWChief Financial OfficerOther4.3k——Jan 3, 2025
CLARK GEORGE C.OfficerOther2.5k——Jan 3, 2025
CAR BRUCEOfficerOther4.8k——Jan 3, 2025
CORIC VLADIMIRChief Executive OfficerOther14.3k——Jan 3, 2025
GENTILE KIMBERLY AOfficerOther3.8k——Jan 3, 2025
CHILDS JOHN WDirectorBuyindirect29.0k$35.94$1.04MDec 30, 2024
CORIC VLADIMIRChief Executive OfficerBuyindirect21.1k$47.50$1000kOct 2, 2024
CHILDS JOHN WDirectorBuyindirect21.1k$47.50$1000kOct 2, 2024

Analyst Notes

Sign in to write

No analyst notes on BHVN yet.

Analyst Ratings

15 analysts covering

PeriodStrong BuyBuyHoldSellStrong SellConsensus
Current39301Buy2.19
1 mo ago49201Buy2.06
2 mo ago49301Buy2.12
3 mo ago410401Buy2.16
Price target$21.47$10.00 – $42.00
+43.1% to target